A cancer blockbuster gets approved in China. Will the floodgates now open?
Bristol-Myers Squibb announced today that its pioneering cancer immunotherapy drug Opdivo has been approved for sale in China.
“Opdivo targets a protein called PD-1, which is effectively a braking signal in the immune system. Cancer cells are incredibly wily when it comes to evading the body’s own natural defenses, and one of the ways they manage this feat is by tricking the immune system into restraining its own attack dogs. So-called “checkpoint inhibitors” like Opdivo—which is often called by its biological name, nivolumab—essentially remove the biological leash, allowing immune cells to freely attack the cancer predator…”
#future = #REALnews #health #medicine #medtech #wellness #tech #innovation #science #design #biotech #biology #xMed #singularity #engineering #ai #artificialintelligence #robots #automation #camcer
Now China’s economy will explode once more.